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A B S T R A C T
A clinical scenario of a young female on 800 mg of sodium valproate (VPA) who has recently failed
lamotrigine (LTG) and levetiracetam (LEV) and who is currently planning a pregnancy is presented.
Currently available data pertaining to the longer-term development of children exposed to antiepileptic
drugs (AEDs) are reviewed along with considerations around the methodology and interpretation of such
research. There is an accumulation of data highlighting signiﬁcant risks associated with prenatal
exposed to VPA, with the level of risk being mediated by dose. The majority of published evidence does
not ﬁnd a signiﬁcant risk associated with carbamazepine (CBZ) exposure in utero for global cognitive
abilities however the evidence for more speciﬁc cognitive skills are unclear. Limited data indicate that
LTG may be a preferred treatment to VPA in terms of foetal outcome but further evidence is required. Too
little data pertaining to LEV exposure is available and a lack of evidence regarding risk of this and other
new AEDs should not be interpreted as evidence of safety.
 2015 Published by Elsevier Ltd on behalf of British Epilepsy Association.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Consider a woman currently seizure free on sodium valproate
(VPA) 800 mg daily, who has previously failed lamotrigine (LTG)
and levetiracetam (LEV) through efﬁcacy. She is taking folic acid
and planning a pregnancy: what can we tell her about the future of
her child? Pre-conceptual decision making is a complex balance of
perceived risk and harm (Fig. 1). It is only through reliable research
into the effect of individual antiepileptic drugs (AED) exposure in
the womb, can we hope to provide the woman comprehensive
information to allow an informed decision regarding choice and
dose of AED. This review considers the key research that directly
measures in utero AED exposure effects on future cognitive and
behavioural development of the commonly used AEDs in clinical
practice.
2. Indirect evidence
AEDs can cause neuronal injury at single dose exposures
therapeutically relevant to humans during critical phases of brain
development in rat models [1]. Evidence of harm is noted both* Corresponding author. Tel.: +44 1213716850.
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changes in offspring and is mediated through a variety of putative
mechanisms [1], with apoptosis most commonly reported [2]. The
teratogenic effects of in-utero exposure of AEDs are established
and discussed by Tomson in this supplement [3]. But in brief,
pregnancy registers internationally consistently highlight in utero
exposure to have an elevated dose-dependent risk from sodium
valproate compared to other commonly used AEDs [4–6].
Understanding of the cognitive development of children exposed
to in utero AEDs lags behind that of congenital malformations;
despite early case reports pertaining to AED associated malforma-
tions often noting that cases also presented with impaired cognitive
functioning [7–9]. Since the turn of the century increased attention
to the potential cognitive risks that may be associated with speciﬁc
AED exposures has occurred, however, data pertaining to newer
drugs is still slow to accumulate. But why should speciﬁc attention
be paid to the cognitive functioning of children exposed in the womb
to AEDs?
Biological plausibility that this group of medications poses a
risk to neuronal development is provided by data from animal
models. Animal studies document altered neuronal development
following exposure in utero to phenobarbital (PB) [10], phenytoin
(PHT) [10], VPA [10–13], carbamazepine (CBZ) [14]. A small
number of studies also indicate that LTG may also alter aspects of
neuronal development [11,15], with LEV being the only AED not to
Fig. 1. The balance of beneﬁt and risk of epilepsy drug treatment in pregnancy.
D. McCorry, R. Bromley / Seizure 28 (2015) 51–5652be associated with such affects to date [16] but research is still
limited. An effective neuronal network is required to support
cognitive functioning with decades of research highlighting
lifelong implications for children who sustain damage to the
neuronal system. Considering then that AEDs are noted in animals
to alter typical neuronal development and the lifelong impact that
such alterations may have for the human child, understanding the
potential risks associated with the speciﬁc AED exposures is critical
in ensuring optimum outcomes for both mother and child.
3. Measurement of cognitive abilities and lifelong implications
The longer term future academic and employment opportu-
nities of the exposed offspring could only be assessed directly
through a prospective longitudinal study which follows them up
into adulthood. However, whether an AED is associated with an
increased risk of cognitive difﬁculty needs to be determined much
faster than such a method would allow and therefore the cognitive
functioning of the child, which is predictive of later educational
outcomes are utilized. The most commonly used method to assess
cognitive functioning in school aged children in the intelligence
test which produces an IQ quotient and is demonstrated to be
relatively stable throughout the lifetime [17]. However, this
measure is far from comprehensive and should be considered as a
global summary for cognitive functioning with consideration given
that substantial strengths and weaknesses in speciﬁc domains (i.e.
language functioning or processing speed) may be masked by such
a measure and that although certain memory systems contribute
to IQ such a measure is unable to measure episodic memory or
complex aspects of other speciﬁc cognitive skills.
Understanding the factors that contribute to cognitive devel-
opment might reasonably be described as complex. Both genetic
and epigenetic effects along with both prenatal and postnatal
environmental factors interact to mediate cognitive outcome
[18,19]. There are, however, a few stables within this set of
complex interactions which are relevant to the study of AED
teratogenicity. Firstly, IQ is a good predictor of educational
attainment. Deary et al. [20] for example demonstrated in over
7000 children that having an IQ in the average range meant that
56% would get the expected average in formal educational
examinations in comparison to just 16% of children whose IQ
was below the average range. A second stable relevant to this topic
is the ﬁnding that parental IQ is a strong predictor of child IQ [18];
stemming from both direct genetic inﬂuences and through the
impact paternal IQ has on the child’s postnatal [21], and you could
even argue, prenatal environment. Thus, the measurement of
cognitive function in the childhood years with the consideration
and adjustment for confounding variables such as parental IQ is
likely to provide a reliable indication of the child’s future level of
functioning and comparisons to unexposed children or childrenexposed to other AEDs allows us to delineate risks associated with
speciﬁc AED treatments.
However, to understand and interpret key research into clinical
decision making we should understand how such abilities are
measured and interpreted. IQ is by far the most ‘famous’ cognitive
function and has a number of negative historical connotations,
however, its correlation with educational outcome means it
remains in useful as a summary of global cognitive function.
The majority of published paediatric IQ tests are available only to
those with the correct training and academic background. Tests are
developed based on cognitive theory and administered to
hundreds or even thousands of children during development
which form its normative population. Knowing how this normative
population performed when given the assessment under stan-
dardized testing conditions means that inferences can be made
about the child who has just completed the assessment either for
clinical or research purposes. The most widely used measures of IQ
are the Wechsler Intelligence Scales [22] which are produced for
adults and children across a number of languages. The mean IQ
score on these measures is 100 with a standard deviation of 15,
with 68% of children assessed falling within the average range,
with 13.6% falling over one standard deviation from the mean with
2.2% falling over two standard deviations from the mean (a score of
below 70). Inferences can therefore be made based on the child’s
scores as to how the child performs in comparison to the normative
population for their age group; reporting what quotient they are
comparable to and also whether they fall within, below or above
the average range (thus is their IQ comparable, above or below the
majority of children their age).
At a group level the mean IQ scores of two groups can be
statistically compared to see if one group provides a lower or
higher mean IQ than the other. It is a common misconception that a
group mean within the average range suggests that there is no
concern for the children within that group. For example, a mean
group IQ of 91, although in the average range, is lower than the
normal population mean of 100 and therefore there will be
increased numbers of children falling within the below average
and impaired ranges as the Gaussian curve, which centres around
the mean, shifts to the left. Therefore although at a group level the
mean is within the average range there will be an increased
frequency of children falling below the average range, which is
critical information when assessing risks. Group means well above
the expected mean of 100 also require investigation, as procedural
or testing artefacts may be falsely inﬂating the mean scores. For
example, a common error is the use of an old IQ test where the
normative sample was collected over 10 years previously.
Comparing a child’s performance to a normative sample collected
10 or more years ago will lead to an inﬂation of the child’s IQ score
due to the phenomenon called the ‘Flynn effect’. The Flynn effects
demonstrate that there are gains in IQ over time to the magnitude
of around 3 points per 10 years [23]. Therefore up to date tests and
normative samples are required to ensure reliable assessment.
IQ is not, however, a measure of a speciﬁc cognitive skill and
there is not a neuroanatomical correlate to IQ; IQ is in fact a
‘summary score’ for a range of more speciﬁc cognitive skills such as
attention, semantic memory, language, processing speed, spatial
and certain executive abilities such as goal orientated behaviour
and task persistence. Thus reliance in research into potential
cognitive effects following exposure in utero to AEDs on IQ may
lead to the masking of more speciﬁc cognitive effects. An IQ score
also will not tell you about certain cognitive skills including
episodic memory, more complex aspects of attention or other
cognitive skills and discrepancies between IQ level and such skills
have been reported [24,25]. Therefore although useful to summa-
rize cognitive function in a research context where you want to
keep the number of statistical comparisons to a minimum and the
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should not be considered to measure cognitive functioning in its
entirety.
In younger children early developing cognitive abilities tend to
be dependent on the emergence of early motor and language
ability and therefore a slightly different assessment approach is
required. The developmental quotient (DQ) is similar to IQ in that it
provides a global summary of the development of skills across
aspects of cognition and has been showed to be predictive of later
cognitive functioning [26]. Two commonly used measures are
the Bayley Scales of Infant and Toddler Development [27] or the
Grifﬁths Mental Development Scales [28] and require the infant to
be observed demonstrating certain responses (i.e. exploration,
copying, verbalizations, pointing etc.) following the presentation of
standardized toys with set instructions across a set number of
trials. Typically, these measurements are used in children under
school age and in particular in children under the age of three years
or where a severe developmental delay is suspected. Similar to IQ
tests, these measures have a normative sample where the mean is
100 and a standard deviation of 15 and therefore the aspects of IQ
interpretation noted above apply here.
4. Other considerations in neurodevelopmental research
In addition to selecting the neurodevelopmental measures and
interpreting them correctly there are a number of other
methodological issues the clinician should consider when review-
ing data pertaining to neurodevelopmental outcome studies in the
context of children exposed to AEDs.
4.1. Power
Given that around 20% of normal developing children are
expected to fall below the average range (over one standard
deviation below the mean) it can be viewed that below average
cognitive development is a fairly common outcome, certainly in
comparison to rates of major congenital malformations which are
rare outcomes in the general population (2–3%). The more
common outcome under investigation the fewer participants
needed to ensure an adequately powered cohort and therefore this
works in favour of the researcher investigating neurodevelop-
mental outcomes [29]. Whilst large numbers of children are
required to study the risk of major malformations, fewer children
are required to investigate cognitive ability. Power is also affected
by the size of the effect under investigation and therefore large
effect sizes will be detectable with smaller groups than more
moderate or milder effect sizes which will require larger numbers
of participants. Typically papers in this area report power
calculations to require between 40 and 50 participants per group
for adequate power to detect moderate to large effect sizes [29–
31], the detection of even larger effect sizes would be possible with
smaller groups [29], however, knowing the effect size you are
looking at prior to the onset of a study is difﬁcult. Thus, although
the assessment and follow up is more time consuming fewer
children in comparison to malformation studies are required for
neurodevelopmental studies to detect large effect sizes.
4.2. Groups
Historically, many research papers would simply report on the
cognitive abilities of a single monotherapy AED exposed group.
Given the differences in prescribing across countries and time
points [32] no two monotherapy groups are likely to be
comparable and conﬂicting ﬁndings become possible. Further,
given the evidence reviewed below, differential outcomes across
the different AEDs demonstrates that a single monotherapy groupwould not provide information required to counsel women about
any potential risks. Therefore evidence to counsel women should
come from speciﬁc AED treated groups and not from a single mixed
AED group.
4.3. Blinded assessments
To ensure that the effects of unconscious biases are reduced
more reliable data will be generated by research where the person
assessing the child’s performance is blinded to where the child
belongs to an experimental or control group.
4.4. Confounders
As noted above when researching cognitive development a
wealth of postnatal inﬂuences come into effect with the collection
of information pertaining to confounders and adjusting for them
statistically is vital. In both general cognitive research and research
speciﬁc to AED exposure parental IQ, socioeconomic status, child
age, gestational age at birth, child gender have all been
documented to be signiﬁcantly associated with child cognitive
outcome and the more reliable studies should statistically address
their impact on the measured outcome.
4.5. Registry studies/prospective studies
As randomized controlled trials are not thought to be ethical the
gold standard for research into neurodevelopmental teratology
studies such as those including AEDs would be a well-designed
observational study. Prospective studies are thought to be more
reliable than retrospective studies as they remove the challenges of
recall bias around teratogen use [33,34]. The utilization of cohorts
of children prospectively enrolled into a malformation register
make use of available cohorts, however, recruitment would be
considered retrospective, which in its self may lead to bias.
However, recent meta-analysis ﬁnds a similar pattern of ﬁndings
across these two study types [35].
A recently completed systematic review ﬁnds that quality of
methodologies in neurodevelopment studies have been variable
but that there is a trend for more recent studies to have more
reliable methodologies [35], which is encouraging.
5. Review of current neurodevelopmental evidence
5.1. Carbamazepine
Carbamazepine has received the most research attention
pertaining to the cognitive abilities of children exposed to AEDs.
The majority of evidence fails to ﬁnd an association between CBZ
exposure and poorer global cognitive development in infancy or IQ
in school aged children in comparison to control children [35–39].
The largest study to date recorded the IQ of 86 children exposed to
CBZ in comparison to 141 children born to women without epilepsy
and failed to ﬁnd a signiﬁcant difference at school age [36].
In the largest prospective study to compare children exposed
to CBZ to other AEDs, the NEAD Study found that the IQ of
children exposed to CBZ was signiﬁcantly higher than that of
the children exposed to VPA and did not differ signiﬁcantly from
the children exposed to either LTG or PHT when the children were
assessed at 3, 4.5 and 6 years of age [30,40,41].
An increased prevalence of autistic spectrum disorders in
children exposed to certain AEDs such a VPA has been documen-
ted. Rasalam et al. [42] reported an increased risk of autistic
spectrum diagnosis in children exposed to CBZ, however, this has
not been replicated by others [43,44], including a large population
based study [44].
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Despite its many years of use the cognitive risks associated with
prenatal exposure to VPA were only really documented since the
turn of the century. The work of Adab and colleagues [39,45]
highlighted that children exposed to VPA were at an increased risk
of requiring educational support and that their IQ was signiﬁcantly
poorer than both controls and children exposed to other AEDs.
These retrospective ﬁndings have since been replicated and
extended with prospective methodologies [30,36,38,40,41,46–
50] and a recent meta analysis found that VPA exposure in the
womb was associated with a signiﬁcant mean difference of
between seven to eleven IQ points in comparison to control
children and children exposed to other AEDs [35]. In context, a
mean IQ score reduction of this magnitude is substantial when it is
considered the standard deviation of these measures is 15. Whilst
meta-analysis is limited to unadjusted mean scores from already
published data the vast majority of the prospective studies
included made adjustment for confounding parental and child
variables and maintained the conclusion; that prenatal exposure to
VPA is associated with an increased risk of poorer cognitive
outcome [30,36,38,40,41,46,47,50]. Of particular note, in the NEAD
study children exposed to PHT, LTG and CBZ demonstrated the
expected correlation between maternal IQ and child IQ, however,
the group exposed to VPA showed no such correlation; increased
maternal IQ was not linked to increased child IQ [41].
Looking across the ages of assessment it is apparent that the
difﬁculties for the children exposed to VPA are present early in
development [30,38,50] and remain into the school aged years
[35]. Early language and motor developmental impairments are
reported in young children exposed to VPA which are consistent
with the report by Moore and colleagues [51] who documented an
increased need to speech and language therapy in the children
exposed to VPA and which has been replicated [39]. Vulnerabil-
ities, in language functioning have also been noted at school age
and appear to be global in nature [49].
There is also evidence from case reports, retrospective and more
recently prospective studies that children exposed to VPA
prenatally are at an increased risk of being diagnosed as having
an autistic spectrum disorder [39,43,44,52]. Christensen et al. [44]
utilized routinely recorded healthcare data to investigate whether
children exposed to VPA were at an increased risk of autistic
spectrum diagnosis and found an absolute risk of 4.42% based on
508 children exposed to VPA monotherapy. This prevalence is
lower than an 8% prevalence which has been reported from
observational studies [39,42,43] and this discrepancy is likely due
to methodological differences across study types.
One of the most important considerations in relation to
treatment in the child bearing years with VPA is its dose. The risk
to cognitive development appears to be mediated by the dose of
VPA with a number of studies reporting decreasing cognitive
abilities with increasing dose [30,38–41,49]. Meador et al. [41] found
doses equal or above 1000 mg per day VPA had a mean IQ of 94
compared to a mean IQ of 104 for doses below this value. Doses of
less than 1000 mg of VPA were associated with a non-signiﬁcantly
lower IQ when compared to CBZ, PHT and LTG [41]. Across all AED
exposures peri-conceptual folate was associated with a higher IQ
[41], however, replication is required here.
5.3. Lamotrigine
Lamotrigine is widely used in the treatment of epilepsy in
women of childbearing age [32,53], however, there is limited
information on cognitive outcomes in children exposed to it in
utero. Bromley and colleagues [38] found infants exposed to LTG
and who were under the age of two years at assessment not todiffer in their early global cognitive development from control
children. Consistently, Cummings et al. [50] also found a non-
signiﬁcant difference in children exposed to LTG in comparison to
controls. Further, data from the NEAD study found the IQ of
children exposed to LTG to be signiﬁcantly higher than the children
exposed to VPA but not signiﬁcantly different from children
exposed to CBZ and PHT [30,40,41].
In terms of speciﬁc cognitive abilities Meador et al. [41] found
superior verbal, non-verbal, memory and executive skills for
school aged children exposed to LTG in comparison to the children
exposed to VPA. Rihtman and colleagues [54], however, noted a
signiﬁcant correlation between dose of LTG and poorer ﬁne motor
abilities, but this was not replicated in the study by Veiby et al.
[55]; although parental rating of motor abilities were used in the
later study. Further research, is required into the cognitive abilities
of children exposed to LTG with particular emphasis on dose.
In the study by Bromley and Colleagues [43] children exposed
to LTG were not at an elevated risk of autistic spectrum diagnosis
in comparison to control children and neither did the large
population study by Christensen et al. [44]. However, Veiby et al.
[55] using parental completed questionnaires reported that at 36
months of age parents indicated concern that their child may show
traits of autistic spectrum disorders more frequently than the
parents of control children.
5.4. Levetiracetam
There are only two published studies to date which assesses the
cognitive abilities of children exposed to LEV in utero; which
highlights the latency between widespread use and teratology risk
or safety information.
The two studies by Shallcross and colleagues have a degree of
overlap in their subjects with 32% of the under two year old cohort
[47] being reassessed between the ages of 3 and 4.5 years [46]. The
global cognitive ability and the language abilities of children
exposed to LEV were comparable to control children at both age
points, whilst signiﬁcant differences were noted for some aspects
of development in comparison to children exposed to VPA [46,47].
Within this data there was noted to be a signiﬁcant effect of dose of
LEV; although the correlation was reportedly weak [47]. Further
research is urgently required and the absence of data should not be
taken as an indication of foetal safety.
6. Unanswered questions and future research
VPA was introduced in the early 1970s yet it has taken over 40
years of use to comprehensively determine its harmful effects on
the cognitive development of unborn child. Future research should
occur more quickly following an AED entering standard usage.
There is a need to conduct standardized blinded assessments,
reporting data in a way that can be used to enable meta analysis.
There is a need to understand how in-utero exposure effects
cognitive and behavioural development not only in childhood but
also with long-term follow-up into adolescent years. There should
be caution about the reliability of risk estimates for VPA at
offspring aged six years as it remains possible the difference
between the VPA exposed children and their peers increase into
adolescence as cognitive complexity increases.
Current practice has moved away from using VPA in women of
childbearing age towards CBZ, LEV and LTG. Currently too little is
known about LTG and LEV and cognitive outcomes in the child,
particularly around potential dose effects. Therefore, the data on
newer AEDs should be considered as very limited, and the
controlled observational data on cognitive outcomes of children
on polytherapy unknown and should not be simply extrapolated
from monotherapy data. Further, too little evidence pertaining to
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should include what we know and what we do not. A lack of
evidence of risk should not be taken as evidence of safety.
Finally, while we as professionals try and understand the risks
and beneﬁts of AED usage in women of childbearing age and through
pregnancy our goal is primarily to inform a woman’s decision
making. Professionals need to understand the woman’s perspective,
form a relationship of trust that allows their concerns over the
tablets they choose to take to be expressed and appreciate that
while we can attempt to give statistical risks in certain scenarios
there is uncertainty both to our current knowledge and to what these
risks mean to the individual.
7. Conclusions
A consistent theme has emerged that VPA exposure in the womb is
a risk for a poorer cognitive outcome than other commonly used AEDs.
The risks appear to lower the mean IQ for the exposed children by
some seven to eleven points and, in addition, there is a greater number
of children with special educational needs and learning difﬁculties.
Prospective studies and a population based registry also indicate a
higher than expected rate of abnormal behavioural development with
autism and autistic spectrum disorder. VPA has a dose effect, with
doses lower than 1000 mg daily appearing, based on current level of
evidence, to be associated with better cognitive outcomes.
Women with epilepsy of childbearing age should ideally be on a
single AED at the lowest effective dose to control seizures, VPA
should generally be avoided when possible, however, the impor-
tance of seizure control should not be underestimated. Women
should be offered high dose folic acid 5 mg peri-conceptually.
Clinicians should be aware that unplanned pregnancy is common
and, for example, accounts for around one third of pregnancies at the
epilepsy-antenatal clinic at Birmingham Women’s Hospital, UK.
Returning to the clinical scenario introduced at the beginning of
this article of the women currently seizure free on VPA 800 mg
daily, who has previously failed LTG and LEV through efﬁcacy. She
would need to be counselled about the teratogenic data of VPA and
the concerns VPA may affect cognitive development highlighted
above balanced with the risk of loss of seizure control; in light of
her current level of dose which appears to carry lower risk if she
elected to conceive on VPA we would support the informed
decision. Whilst the risk posed in terms of malformations could
be eliminated if VPA was introduced from 12 weeks, no such
reassurance can be given for cognitive development with foetal
brain maturation continuing throughout pregnancy (and into the
postnatal years). Little is known about the cognitive outcomes of
monotherapy or dual therapy with high dose LTG and LEV and this
too would be presented to the female to aid her treatment
decisions. Finally decisions on AED choice and dose are not one of
the events and should there be loss of seizure control in pregnancy,
consultation and risk information provision would be required and
counselling should be seen as an ongoing discussion between the
prescribing clinician and the patient.
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